FY2025 · ended Dec 31, 2025 · Revenue $2.80M, -38.2% YoY · Filed Mar 24, 2026
Absci Corp (ABSI) files with the SEC under industry code 8731, Services-Commercial Physical & Biological Research. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $2.8 million and a net loss of $115.2 million. Free cash flow was -$94.0 million. As of Jun 30, 2026 it held $201.1 million in cash and investments and $3.7 million in total debt.
Revenue (TTM)
$1.56M
-62.3% vs year-ago TTM
Net income (TTM)
$-121.08M
-6.9% vs year-ago TTM
Operating cash flow (TTM)
$-108.08M
-41.5% vs year-ago TTM
Free cash flow (TTM)
$-108.97M
-42.0% vs year-ago TTM
EPS (TTM)
$-0.80
+15.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
153.02M
+20.2% vs prior year
Net cash
$197.46M
as of Jun 30, 2026
Operating margin
-8084.5%
FY 2026
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- ABSI (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Vancouver, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1672688
- Former names
- AbSci, LLC (until Dec 19, 2019)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- OmniAb, Inc. OABI
- NRC Health NRC
- Maxcyte, Inc. MXCT
All 17 Services-Commercial Physical & Biological Research companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $2.8M | $4.5M | $5.7M | $4.5M | $4.0M |
| Operating income | -$120.3M | -$108.9M | -$115.5M | -$106.8M | -$75.2M |
| Net income | -$115.2M | -$103.1M | -$110.6M | -$104.9M | -$101.0M |
| Diluted EPS | -$0.84 | -$0.94 | -$1.20 | -$1.15 | -$2.08 |
| Operating cash flow | -$92.9M | -$72.4M | -$64.6M | -$81.3M | -$60.6M |
| Free cash flow | -$94.0M | -$72.8M | -$65.5M | -$97.5M | -$98.6M |
| Total assets | $216.3M | $213.6M | $217.3M | $321.0M | $426.2M |
| Total liabilities | $26.8M | $34.5M | $41.1M | $46.6M | $60.1M |
| Stockholders' equity | $189.4M | $179.1M | $176.2M | $274.4M | $366.1M |
| Cash and investments | $156.1M | $41.2M | $72.4M | $60.0M | $252.6M |
| Total debt | $4.4M | $10.1M | $16.0M | $23.0M | $20.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Jun 24, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Other events
|
Jun 24, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 5, 2026 | Jun 4, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
All 360 Absci Corp SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.